UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations

Journal of Crohn's and colitis, 2016-02, Vol.10 (2), p.127-132

2016

Volltextzugriff (PDF)

The nutritional status and factors contributing to malnutrition in children with chronic pancreatitis

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2014-07, Vol.14 (4), p.275-279

2014

Volltextzugriff (PDF)

Etiology of chronic pancreatitis in children

HPB (Oxford, England), 2016-04, Vol.18, p.e318-e319

2016

Volltextzugriff (PDF)

Prevalence rate of autoimmune pancreatitis in children with chronic pancreatitis

HPB (Oxford, England), 2016-04, Vol.18, p.e332-e332

2016

Volltextzugriff (PDF)

Anatomic anomalies of pancreatic duct in children with chronic pancreatitis

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2012-11, Vol.12 (6), p.583-583

2012

Volltextzugriff (PDF)

Clinical manifestation of chronic pancreatitis associated with SPINK1 mutations in children

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2012-11, Vol.12 (6), p.565-565

2012

Volltextzugriff (PDF)

P395 The frequency of SARS-CoV-2 infection and the impact of vaccination on the disease morbidity in Polish pediatric patients with Inflammatory Bowel Disease treated with biologic therapies

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i825-i825

2024

Volltextzugriff (PDF)

P393 The frequency of COVID-19 infection and the impact of vaccination on the disease morbidity in Polish pediatric patients with Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i823-i823

2024

Volltextzugriff (PDF)

P223 The usefulness of tissue calprotectin in pediatric Crohn’s disease – a pilot study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i376-i377

2023

Volltextzugriff (PDF)

P750 Predictors of quick remission after cyclosporine A therapy in Paediatric ulcerative colitis

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S490-S490

2018

Volltextzugriff (PDF)

P275 New non-invasive biomarkers of intestinal inflammation in pediatric inflammatory bowel diseases and their correlation with fecal calprotectin – pilot study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i311-i312

2022

Volltextzugriff (PDF)

P216 Effect of the Crohn’s disease exclusion diet (CDED) on the fecal calprotectin level in children with active Crohn’s disease

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i270-i270

2022

Volltextzugriff (PDF)

P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn’s Disease: A phase 2 double-blind, randomized, placebo-controlled study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i505-i507

2023

Volltextzugriff (PDF)

748 EFFICACY OF STANDARD OF CARE THERAPY FOLLOWING EXPERIMENTAL DEBIO 025 TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

Journal of hepatology, 2010, Vol.52, p.S291-S291

2010

Volltextzugriff (PDF)

P359 Budesonide MMX in paediatric ulcerative colitis

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S283-S284

2019

Volltextzugriff (PDF)

Diagnosis of gastroesophageal reflux and anti-reflux procedures among polish children with gastrostomies: a 10-year nationwide analysis

European journal of clinical nutrition, 2013-11, Vol.67 (11), p.1169-1174

2013

Volltextzugriff (PDF)

OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i4-i5

2024

Volltextzugriff (PDF)

OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i62-i64

2024

Volltextzugriff (PDF)

OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i7-i9

2024

Volltextzugriff (PDF)

P770 Can we predict mucosal inflammation in children with inflammatory bowel disease without colonoscopy?

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S500-S500

2018

Volltextzugriff (PDF)

OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i56-i59

2023

Volltextzugriff (PDF)

P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1737-i1738

2024

Volltextzugriff (PDF)

P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1653-i1654

2024

Volltextzugriff (PDF)

DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i92-i93

2024

Volltextzugriff (PDF)

P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i623-i624

2023

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(114)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations

The nutritional status and factors contributing to malnutrition in children with chronic pancreatitis

Etiology of chronic pancreatitis in children

Prevalence rate of autoimmune pancreatitis in children with chronic pancreatitis

Anatomic anomalies of pancreatic duct in children with chronic pancreatitis

Clinical manifestation of chronic pancreatitis associated with SPINK1 mutations in children

P395 The frequency of SARS-CoV-2 infection and the impact of vaccination on the disease morbidity in Polish pediatric patients with Inflammatory Bowel Disease treated with biologic therapies

P393 The frequency of COVID-19 infection and the impact of vaccination on the disease morbidity in Polish pediatric patients with Inflammatory Bowel Disease

P223 The usefulness of tissue calprotectin in pediatric Crohn’s disease – a pilot study

P750 Predictors of quick remission after cyclosporine A therapy in Paediatric ulcerative colitis

P275 New non-invasive biomarkers of intestinal inflammation in pediatric inflammatory bowel diseases and their correlation with fecal calprotectin – pilot study

P216 Effect of the Crohn’s disease exclusion diet (CDED) on the fecal calprotectin level in children with active Crohn’s disease

P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn’s Disease: A phase 2 double-blind, randomized, placebo-controlled study

748 EFFICACY OF STANDARD OF CARE THERAPY FOLLOWING EXPERIMENTAL DEBIO 025 TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

P359 Budesonide MMX in paediatric ulcerative colitis

Diagnosis of gastroesophageal reflux and anti-reflux procedures among polish children with gastrostomies: a 10-year nationwide analysis

OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial

OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study

OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study

P770 Can we predict mucosal inflammation in children with inflammatory bowel disease without colonoscopy?

OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results

P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study

P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study

DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial

P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study

Suchergebnisse filtern